All In Biotech

NDA 213422 · Mc2

Wynzora

Betamethasone Dipropionate, Calcipotriene · Topical · Vitamin D Analog

Last checked: Nov 19, 2026Latest source record: Jul 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jul 20, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

30 Phase 3, 11 recruiting

FAERS reports

428

296 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 29, 2023.

WYNZORA Cream is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. WYNZORA Cream is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. ( 1 )

Mechanism: WYNZORA Cream combines the pharmacological effects of calcipotriene as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in plaque psoriasis are unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 20, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • WYNZORA · BETAMETHASONE DIPROPIONATE 0.064%; CALCIPOTRIENE 0.005% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • psoriasis123
  • drug ineffective70
  • pruritus53
  • fatigue40
  • pain37
  • arthralgia33
  • diarrhoea32
  • rash31
  • nasopharyngitis30
  • inappropriate schedule of product administration29
  • psoriatic arthropathy29
  • cellulitis26

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201011
201216
20141
20151
201639
201738
201834
201950
202049
202138
202247
202346
202428
202514
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 225 on PubMed

Sponsor: Mc2

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.